Key Points
- CEO Vlad Vitoc purchased 73,000 MAIA shares at an average price of $1.37, investing approximately $100,010 and increasing his stake by 7.48% to 1,049,121 shares.
- MAIA shares opened at $1.34, with a market capitalization of approximately $81.5 million and a 52-week trading range of $0.87 to $3.19.
- The company reported a quarterly loss of $0.13 per share, missing analyst expectations by $0.02. Institutional investors and hedge funds own 5.65% of MAIA, with several funds establishing new positions recently.
MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA - Get Free Report) CEO Vlad Vitoc acquired 73,000 shares of the firm's stock in a transaction that occurred on Monday, September 14th. The shares were purchased at an average price of $1.37 per share, with a total value of $100,010.00. Following the acquisition, the chief executive officer owned 1,049,121 shares of the company's stock, valued at approximately $1,437,295.77. This trade represents a 7.48% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
MAIA Biotechnology Stock Performance
Shares of NYSEAMERICAN:MAIA opened at $1.34 on Wednesday. MAIA Biotechnology, Inc. has a 52 week low of $0.87 and a 52 week high of $3.19. The company has a market capitalization of $81.51 million, a PE ratio of -2.16 and a beta of 0.25. The company has a 50 day moving average price of $1.35 and a two-hundred day moving average price of $1.38.
MAIA Biotechnology (NYSEAMERICAN:MAIA - Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, sell-side analysts forecast that MAIA Biotechnology, Inc. will post -0.54 earnings per share for the current year.
Institutional Trading of MAIA Biotechnology
Several hedge funds have recently added to or reduced their stakes in MAIA. Centric Wealth Management bought a new position in MAIA Biotechnology during the second quarter worth about $1,107,000. Cable Car Capital LP bought a new stake in shares of MAIA Biotechnology in the second quarter worth about $741,000. BlackRock Inc. bought a new stake in shares of MAIA Biotechnology in the second quarter worth about $580,000. Susquehanna International Group LLP acquired a new stake in shares of MAIA Biotechnology during the second quarter worth about $51,000. Finally, PVG Asset Management Corp acquired a new stake in shares of MAIA Biotechnology during the first quarter worth about $46,000. Institutional investors and hedge funds own 5.65% of the company's stock.
MAIA Biotechnology Company Profile
(
Get Free Report)
MAIA Biotechnology, Inc is a clinical‐stage biopharmaceutical company developing a proprietary platform for site‐specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody‐based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high‐contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.
The company's pipeline includes several antibody‐radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
